ArticleFrontiers in pharmacology2026
SSRIs-induced liver injury adverse events: a data-based retrospective study and investigation of potential toxicological mechanisms.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To systematically evaluate safety signals of selective serotonin reuptake inhibitors (SSRIs) associated with drug-induced liver injury (DILI) using the FAERS database, and to explore potential toxicological mechanisms through drug-gene interaction network analysis. Methods: Adverse event data for six SSRIs (2013-2023) were extracted from FAERS. Descriptive analysis and disproportionality signal detection (ROR, BCPNN) were performed. Time to DILI onset and factors influencing mortality were analyzed. Network pharmacology explored drug-gene interactions. Due to the absence of individual-level clinical data in FAERS, we could not apply the updated RUCAM, the gold standard for DILI causality assessment. Results: DILI reports were most frequent in patients aged 18-64 years and in females. Sertraline had the highest number of reports; fluvoxamine the fewest. Common signals across SSRIs included hepatocellular injury and necrosis. Fluoxetine showed unique signals for hepatic steatosis, paroxetine for chronic active hepatitis, and sertraline for severe liver failure (e.g., primary biliary cholangitis, hemorrhagic hepatic cyst). Median time to onset was within the first month of treatment. Age 18-44 years (OR = 3.03, 95% CI: 1.12-8.18) and low body weight ≤60 kg (OR = 0.45, 95% CI: 0.18-1.14) were significant predictors of mortality. Network analysis suggested shared mechanisms (e.g., CYP450 dysfunction, apoptosis dysregulation) and drug-specific pathways (e.g., PI3K-Akt for sertraline, IL-17 signaling for fluoxetine/fluvoxamine). Conclusion: DILI safety signals for SSRIs are most frequent within the first month of treatment, particularly in female patients. Considerable variability in hepatotoxicity profiles among SSRIs supports drug-specific monitoring. These hypothesis-generating findings provide a basis for personalized risk assessment and require confirmation in prospective studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.